EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Murine cytomegalovirus reactivation concomitant with acute graft-versus-host disease is controlled by antibodies

Martina Seefried, Nadine Hundhausen, Irena Kroeger, Maike Büttner-Herold, Petra Hoffmann, Matthias Edinger, Evelyn Ullrich, Friederike Berberich-Siebelt, William J Britt, Michael Mach, Thomas H Winkler

JCI Insight · 08.03.2023 · 8 (5)

DOI: 10.1172/jci.insight.149648 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, online erschienen am 08.03.2023. Verfasst von Martina Seefried und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany. Hauptthemen laut MEDLINE: Muromegalovirus, Cytomegalovirus Infections, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Deutsche Forschungsgemeinschaft, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reactivation of human cytomegalovirus (HCMV) from latency is a frequent complication following hematopoietic stem cell transplantation (HSCT). The development of acute graft-versus-host disease (GVHD) is a significant risk factor for HCMV disease. Using a murine GVHD model in animals latently infected with murine CMV (MCMV), we studied preventive and therapeutic interventions in this high-risk scenario of HSCT. Mice latently infected with MCMV experienced reactivated MCMV and developed disseminated MCMV infection concomitant with the manifestations of GVHD. Dissemination was accompanied by accelerated mortality. We demonstrate that MCMV reactivation and dissemination was modulated by MCMV-specific antibodies, thus demonstrating in vivo protective activity of antiviral antibodies. However, the efficacy of serum therapy required repetitive doses of high-titer immune serum secondary to the shortened serum half-life of IgG in animals with GVHD. In a complementary approach, treatment of GVHD by adoptive transfer of donor-derived Tregs facilitated production of MCMV-specific antibodies from newly developing donor-derived B cells. Together, our findings strongly suggest that antibodies play a major role in controlling recurrent MCMV infection that follows GVHD, and they argue for reassessing the potential of antibody treatments as well as therapeutic strategies that enhance de novo antibody development against HCMV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MuromegalovirusCytomegalovirus InfectionsGraft vs Host DiseaseHematopoietic Stem Cell TransplantationMiceHumansAnimalsCytomegalovirusAntibodies, Viral

Stichwörter der Autor:innen

HematologyImmunologyStem cell transplantation

Substanzen

Antibodies, Viral

Autor:innen und Institutionen

  • Department of Biology, Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Institute of Pathology, University of Würzburg, Würzburg, Germany.
  • Department of Internal Medicine 5, Hematology and Oncology, University Hospital, Erlangen, Germany.
  • Department of Nephropathology, Institute of Pathology, FAU, Erlangen, Germany.
  • Department of Internal Medicine III, Hematology and Oncology, University Hospital, Regensburg, Germany and LIT - Leibniz Institute for Immunotherapy, University Regensburg, Regensburg, Germany.
  • Experimental Immunology, Department for Children and Adolescents Medicine, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Förderung

  • NIAID NIH HHS
  • Deutsche Forschungsgemeinschaft
  • NIH

Zitieren

APA

Seefried, M., Hundhausen, N., Kroeger, I., Büttner-Herold, M., Hoffmann, P., Edinger, M., Ullrich, E., Berberich-Siebelt, F., Britt, W. J., Mach, M., & Winkler, T. H. (2023). Murine cytomegalovirus reactivation concomitant with acute graft-versus-host disease is controlled by antibodies. JCI Insight, 8(5). https://doi.org/10.1172/jci.insight.149648

Vancouver

Seefried M, Hundhausen N, Kroeger I, Büttner-Herold M, Hoffmann P, Edinger M, et al. Murine cytomegalovirus reactivation concomitant with acute graft-versus-host disease is controlled by antibodies. JCI Insight. 2023;8(5). doi:10.1172/jci.insight.149648

BibTeX
@article{Seefried2023,
  author = {Seefried, Martina and Hundhausen, Nadine and Kroeger, Irena and Büttner-Herold, Maike and Hoffmann, Petra and Edinger, Matthias and Ullrich, Evelyn and Berberich-Siebelt, Friederike and Britt, William J and Mach, Michael and Winkler, Thomas H},
  title = {Murine cytomegalovirus reactivation concomitant with acute graft-versus-host disease is controlled by antibodies},
  journal = {JCI Insight},
  year = {2023},
  volume = {8},
  number = {5},
  doi = {10.1172/jci.insight.149648}
}
Kostenlos starten →